An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

  • Kaplan, Zane (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/2019/QMS/50855
NMA SSA Reference Number: SSA/50855/MonH-2019-172374(v1)
Monash Health Ref: RES-19-0000-348X
Effective start/end date24/06/1923/06/24


  • clinical trial
  • phase 1/2 study
  • treatment efficacy
  • Immune Thrombocytopenic Purpura